Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
Status:
Terminated
Trial end date:
2023-10-23
Target enrollment:
Participant gender:
Summary
A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral
activity of EXS21546 in combination with a PD-1 inhibitor in patients with advanced solid
tumours.